And Galena Biopharma ( GALE ) disclosed that it had received a new patent from Japan. The biopharmaceutical company said it received a notice from the Japanese Patent Office for NeuVax covering the use of NeuVax alone or in combination with other agents to prevent recurrence of any HER2/neu expressing breast cancer tumor having an immunohistochemistry ( IHC ) level of 1+ or 2+, or a fluorescence in situ hybridization ( FISH ) rating of less than about 2.0.
Shares in the company were trading 1.69% higher at $6.96 during Tuesday's pre-market trading session. Over the past 52 weeks, the company has traded between $1.56 and $7.77.